Agendia Level 1B Evidence Shows MammaPrint is the First and

Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients

Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrint's ability to identify strongest candidates for extended endocrine therapy among HR+HER2-

Related Keywords

Kostenloser Wertpapierhandel , Gerrit Jan Liefers , Kerry Harrington , Agendia Inc , Linkedin , Professor Of Laboratory Medicine , Facebook , Antonio Breast Cancer Symposium , Laboratory Medicine , Applied Genomics , California San Francisco , Helen Diller Family Comprehensive Cancer Center , Mammaprint Low Risk , Mammaprint High Risk , Mammaprint Ultralow Risk , Geriatric Oncology Group , Leiden University Medical Center , Agendia , Level , Evidence , Shows , Mammaprint , First , Only , Leared , Gene , Expression , Profiling , Pest , Redict , Benefit , Rom , Xtended , Ndocrine , Therapy , Early , Stage , Breast , Dancer , Patients ,